Human P450 metabolism of warfarin

Pharmacology and Therapeutics

Volumn 73, Issue 1, 1997, Pages 67-74

  Kaminsky, Laurence S ^a,b   Zhang, Zhi Yi ^b  

^a WADSWORTH CENTER   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

CYP2C9; CYP3A4; cytochrome P450; human metabolism; R warfarin; S warfarin

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE; WARFARIN;

CATALYSIS; DRUG METABOLISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; PRIORITY JOURNAL; REVIEW;

CATALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; STEREOISOMERISM; WARFARIN;

EID: 0031015345     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(96)00140-4     Document Type: Review

References (57)

1. Abernethy, D. R., Kaminsky, L. S. and Dickinson, T. H. (1991) Selective inhibition of warfarin metabolism by diltiazem in humans. J. Pharmacol. Exp. Ther. 257: 411-415.
2. Banfield, C., O'Reilly, R., Chan, E. and Rowland, M. (1983) Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. Br. J. Clin. Pharmacol. 16: 669-675.
3. Batty, K. T., Davis, T. M., Ilett, K. F., Dusci, L. J. and Langton, S. R. (1995) The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. Br. J. Clin. Pharmacol. 39: 305-311.
4. Bertilsson, L. (1995) Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin. Pharmacokinet. 29: 192-209.
5. Brian, W. R., Sari, M. A., Iwasaki, M., Shimada, T., Kaminsky, L. S. and Guengerich, F. P. (1990) Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry 29: 11280-11292.
6. Chang, M., Tybring, G., Dahl, M. L., Gotharson, E., Sagar, M., Seensalu, R. and Bertilsson, L. (1995) Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br. J. Clin. Pharmacol. 39: 511-518.
7. Gotoh, O. (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J. Biol. Chem. 267: 83-90.
8. Heimark, L. D. and Trager, W. F. (1984) The preferred solution conformation of warfarin at the active site of cytochrome P-450 based on the CD spectra in octanol/water model system. J. Med. Chem. 27: 1092-1095.
9. Heimark, L. D., Gibaldi, M., Trager, W. F., O'Reilly, R. A. and Goulart, D. A. (1987) The mechanism of the warfarin-rifampin drug interaction in humans. Clin. Pharmacol. Ther. 42: 388-394.
10. Hermans, J. J. and Thijssen, H. H. (1989) The in vitro ketone reduction of warfarin and analogues. Substrate stereoselectivity, product stereoselectivity and species differences. Biochem. Pharmacol. 38: 3365-3370.
11. Hermans, J. J. and Thijssen, H. H. (1992) Stereoselective acetonyl side chain reduction of warfarin and analogs: partial characterization of two cytosolic carbonyl reductases. Drug Metab. Dispos. 20: 268-274.
12. Hermans, J. J. and Thijssen, H. H. (1993) Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br. J. Pharmacol. 110: 482-490.
13. Hunt, C. M., Westerkam, W. R. and Stave, G. M. (1992) Effect of age and gender on the activity of human hepatic CYP3A. Biochem. Pharmacol. 44: 275-283.
14. Ikawa, M., Stahmann, M. A. and Link, K. P. (1944) Studies on 4-hydroxycoumarins. V. The condensation of alpha, beta-unsaturated ketones with 4-hydroxycoumarin. J. Am. Chem. Soc. 66: 902-906.
15. Ishizaki, T., Chiba, K., Manabe, K., Koyama, E., Hayashi, M., Yasuda, S., Horai, Y., Tomono, Y., Yamato, C. and Toyoki, T. (1995) Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation. Clin. Pharmacol. Ther. 58: 155-164.
16. Israel, D. S., Stotka, J., Rock, W., Sintek, C. D., Kamada, A. K., Klein, C., Swim, W. R., Pluhar, R. E., Toscano, J. P., Lettieri, J. T., Heller, A. H. and Polk, R. E. (1996) Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin. Clin. Infect. Dis. 22: 251-256.
17. Jansing, R. L., Chao, E. S. and Kaminsky, L. S. (1992) Phase II metabolism of warfarin in primary culture of adult rat hepatocytes. Mol. Pharmacol. 41: 209-215.
18. Jones, B. C., Hawksworth, G., Newlands, A., Morsman, J., Tute, M. S. and Smith, D. A., (1996) Putative active site template model for cytochrome P4502C9 (tobutamide hydroxyalse). Drug Metab. Dispos. 24: 260-266.
19. Kaminsky, L. S. (1989) Warfarin as a probe of cytochromes P-450 function. Drug Metab. Rev. 20: 479-487.
20. Kaminsky, L. S., Dunbar, D. A., Wang, P. P., Beaune, P., Larrey, D., Guengerich, F. P., Schnelmann, R. G. and Sipes, I. G. (1984) Human hepatic cytochrome P-450 composition as probed by in vitro microsomal metabolism of warfarin. Drug Metab. Dispos. 12: 470-477.
21. Kaminsky, L. S., de Morais, S. M., Faletto, M. B., Dunbar, D. A. and Goldstein, J. A. (1993a) Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol. Pharmacol. 43: 234-239.
22. Kaminsky, L. S., Obach, R. S. and Fasco, M. J. (1993b) Cytochrome P450: probes of active site residue. In: Handbook of Experimental Pharmacology, pp. 183-194, Schenkman, J. B. and Greim, H. (eds.) Springer-Verlag, Berlin.
23. Kates, R. E., Yee, Y-G. and Kirsten, E. B. (1987) Interaction between warfarin and propafenone in healthy volunteer subjects. Clin. Pharmacol. Ther. 42: 305-311.
24. Kunze, K. L., Eddy, A. C., Gibaldi, M. and Trager, W. F. (1991) Metabolic enantiomeric interactions: the inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin. Chirality 3: 24-29.
25. Lewis, J., Trager, W. F., Chang, K. K., Breckenridge, A., Orme, M., Rowland, M. and Schary, W. (1974) Warfarin, stereochemical aspects of metabolism and the interaction with phenylbutazone. J. Clin. Invest. 53: 1607-1617.
26. Li, A. P., Rasmussen, A., Xu, L. and Kaminski, D. L. (1995) Rifampicin induction of lidocaine metabolism in cultured human hepatocytes. J. Pharmacol. Exp. Ther. 274: 673-677.
27. Mancy, A., Broto, P., Dijols, S., Dansette, P. M. and Mansuy, D. (1995) The substrate binding site of human liver cytochrome P4502C9: an approach using designed tienilic acid derivatives and molecular modeling. Biochemistry 34: 10365-10375.
28. Moreland, A. T. and Hewick, D. S. (1975) Studies on a ketone reductase in human and rat liver and kidney soluble fraction using warfarin as a substrate. Biochem. Pharmacol. 24: 1953-1957.
29. Morsman, J. M., Smith, D. A., Jones, B. C. and Hawksworth, G. M. (1995) Role of hydrogen-bonding in substrate structure-activity relationships for CYP2C9. In: Proceedings of the 4th International ISSX Meeting, Seattle, WA, August 27-31, Vol. 8, p. 259, ISSX, Bethesda.
30. Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., Gunsalus, I. C. and Nebert, D. W. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6: 1-42.
31. Obach, R. S., Spink, D. C., Chen, N. and Kaminsky, L.S. (1992) Azidowarfarin photoaffinity probes of purified rat liver cytochrome P4501A1. Arch. Biochem. Biophys. 294: 215-222.
32. O'Reilly, R. A. (1975) Interaction of chronic daily warfarin therapy and rifampin. Ann. Intern. Med. 83: 506-508.
33. O'Reilly, R. A. (1976) The stereoselective interaction of warfarin and metronidazole in man. N. Engl. J. Med. 295: 354-357.
34. O'Reilly, R. A. and Goulart, D. A. (1981) Comparative interaction of sulfinpyrazone and phenylbutazone with racemic warfarin: alteration in vivo of free fraction of plasma warfarin. J. Pharmacol. Exp. Ther. 219: 691-694.
35. O'Reilly, R. A., Trager, W. F., Rettie, A. E. and Goulart, D. A. (1987) Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin. Pharmacol. Ther. 42: 290-294.
36. Parker, A. C., Preston, T., Heaf, D., Kitteringham, N. R. and Choonara, I. (1994) Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test. Br. J. Clin. Pharmacol. 38: 573-576.
37. Parkinson, A. (1996) Biotransformation of xenobiotics. In: Casarett and Doull's Toxicology: The Basic Science of Poisons, 5th edn., pp. 113-186, Klaassen, C.D., Amdur, M.O. and Doull, J. (eds.) McGraw-Hill, New York.
38. Rettie, A. E., Eddy, A. C., Heimark, L. D., Gibaldi, M. and Trager, W. F. (1989) Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab. Dispos. 17: 265-270.
39. Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. F., Eddy, A. C., Aoyama, T., Gelboin, H. V., Gonzalez, F. J. and Trager, W. F. (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5: 54-59.
40. Rettie, A. E., Wienkers, L. C., Gonzalez, F. J., Trager, W. F. and Korzekwa, K. R. (1994) Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4: 39-42.
41. Sadrieh, N. and Synderwine, E. G. (1995) Cytochromes P450 in cynomolgus monkeys mutagenically activate 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) but not 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx). Carcinogenesis 16: 1549-1555.
42. Shapiro, S. (1953) Warfarin sodium derivative (coumadin sodium): intravenous hypoprothrombinemia-inducing agent. Angioiogy 4: 380-390.
43. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F.P. (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270: 414-423.
44. Shimodaira, H., Takahashi, K., Kano, K., Matsumoto, Y., Uchida, Y. and Kudo, T. (1996) Enhancement of anticoagulant action by warfarin-benzbromarone interaction. J. Clin. Pharmacol. 36: 168-174.
45. Spaldin, V., Madden, S., Pool, W. F., Woolf, T. F. and Park, B. K. (1994) The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br. J. Clin. Pharmacol. 38: 15-22.
46. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6: 341-349.
47. Sutfin, T., Balmer, K., Bostrom, H., Eriksson, S., Hoglund, P. and Paulsen, O. (1989) Stereoselective interaction of omeprazole with warfarin in healthy men. Ther. Drug Monit. 11: 176-184.
48. Toon, S., Low, L. K., Gibaldi, M., Trager, W. F., O'Reilly, R. A., Motley, C. H. and Goulart, D. A. (1986) The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin. Pharmacol. Ther. 39: 15-24.
49. Toon, S., Hopkins, K. J., Garstang, F. M., Aarons, L., Sedman, A. and Rowland, M. (1987) Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects. Clin. Pharmacol. Ther. 42: 33-41.
50. Trager, W. F. (1989) Stereochemistry of cytochrome P-450 reactions. Drug Metab. Rev. 20: 489-496.
51. Trager, W. F., Lewis, J. and Garland, W. A. (1970) Mass spectral analysis in the identification of human metabolites of warfarin. J. Med. Chem. 13: 1196-1204.
52. Unge, P., Svedberg, L. E., Nordgren, A., Blom, H., Andersson, T., Lagerstrom, P. O. and Idstrom, J. P. (1992) A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br. J. Clin. Pharmacol. 34: 509-512.
53. Wang, P. P., Beaune, P., Kaminsky, L. S., Dannan, G. A., Kadlubar, F. F., Larrey, D. and Guengerich, F. P. (1983) Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. Biochemistry 22: 5375-5383.
54. Wells, P. H., Holbrook, A. M., Crowther, N. R. and Hirsh J. (1994) Interactions of warfarin with drugs and food. Ann. Intern. Med. 121: 676-683.
55. Wienkers, L., Storch, E., Kunze, K., Rettie, A. and Trager, W. (1996) The formation of (R)-8-hydroxywarfarin in human liver microsomes: a new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab. Dispos. 24: 610-614.
56. Zhang, Z., Fasco, M. J., Huang, Z., Guengerich, F. P. and Kaminsky, L. S. (1995) Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe. Drug Metab. Dispos. 23: 1339-1345.
57. 462: assessment of a role for the rare allele in carcinogenesis. Cancer Res. 56: 3926-3933.